Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic empagliflozin + linagliptin 25/5 mg vs Glyxambi under fasting in healthy Thai volunteers
TCTR20241016004Phase 1Unknown
- Sponsor
- International Bio Service
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin, empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Status: unknown.
02
Drugs
empagliflozin + linagliptinempagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20241016004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241016004.